25.03.2024 • News

Johnson Matthey to Sell its Medical Device Components Business

UK’s Johnson Matthey (JM) has signed a definitive agreement to sell 100% of its Medical Device Components (MDC) business to Montagu Private Equity for $700 million (£550 million).

The MDC business, which produces components for medical devices with a focus on precious metal alloys and nitinol for global customers, operates manufacturing sites in San Diego, USA; Mexicali, Mexico; and Tullamarine, Australia.

With the sale of the MDC business and the already completed sale of its Battery Systems business, JM said that it has concluded the divestment program for its Value Businesses, originally announced in May 2022.

The transaction, which is subject to regulatory approval, is expected to be completed in the third quarter of 2024.

Liam Condon, CEO of Johnson Matthey, said: "Today’s announcement represents a significant milestone in our disposals program announced in May 2022. As a JM business, MDC has delivered technological differentiation and good growth to the critical health sector. We welcome Montagu’s plans to continue the investment and growth plans at MDC.”

"We are pleased that this concludes our Value Businesses disposal program which will deliver benefits to JM shareholders in terms of value realization, simplification and increased focus on our growth businesses, where JM has a proven ability to win," Condon added.

© Swapan - stock.adobe.com
© Swapan - stock.adobe.com

Company

Johnson Matthey

Orchard Road
SG8 5HE Royston, Herts
UK

Company contact







Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.